(Q56896528)

English

Therapeutic antibody fragments with prolonged in vivo half-lives

article by A P Chapman et al published August 1999 in Nature Biotechnology

In more languages

edit

Statements

instance of

scholarly article

0 references

title

Therapeutic antibody fragments with prolonged in vivo half-lives (English)

0 references

1 reference

A P Chapman

1

0 references

P Antoniw

series ordinal

2

0 references

M Spitali

series ordinal

3

0 references

S West

series ordinal

4

0 references

S Stephens

series ordinal

5

0 references

D J King

series ordinal

6

0 references

language of work or name

English

0 references

publication date

August 1999

0 references

published in

Nature Biotechnology

0 references

volume

17

0 references

page(s)

780-3

0 references

issue

8

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/11717

0 references

cites work

Human antibodies by design.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

21 January 2018

Antibodies stage a comeback in cancer treatment.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

21 January 2018

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

21 January 2018

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

21 January 2018

Assembly of a functional immunoglobulin Fv fragment in Escherichia coli

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

21 January 2018

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

21 January 2018

High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

21 January 2018

Stabilization of substances in circulation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

F(ab')2 molecules made from Escherichia coli produced Fab' with hinge sequences conferring increased serum survival in an animal model

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2F11717

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1038/11717

0 references

Dimensions Publication ID

1049234928

0 references

PubMed ID

10429243

0 references

(Q56896528)

Therapeutic antibody fragments with prolonged in vivo half-lives

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)